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Luis Pérez-Arellano2,3, Beatriz Crego-Vicente1, Juan Garcı́a-Bernalt Diego1, Julio López-
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Abstract
Background
Schistosoma mansoni is the main species causing hepatic and intestinal schistosomiasis in
Sub-Saharan Africa, and it is the only species in South America. Adult stages of the parasite
reside in the mesenteric venous plexus of infected hosts, and eggs are shed in feces. Col-
lecting patient stool samples for S. mansoni diagnostic purposes is difficult in large-scale
field trials. Urine samples would be an alternative approach for molecular S. mansoni detec-
tion since they have several advantages over stool samples, including better handling, man-
agement and storage. Additionally, loop-mediated isothermal amplification (LAMP)
technology is a powerful molecular diagnostic tool for infectious diseases, particularly under
field conditions in developing countries. The present study aimed to assess the effective-
ness of our previously developed LAMP assay (SmMIT-LAMP) for S. mansoni-specific
detection in clinical urine samples.
Methodology/Principal findings
The sensitivity of SmMIT-LAMP in urine was established in simulated fresh human urine
samples artificially spiked with genomic DNA from S. mansoni. LAMP for 120 min instead of
60 min improved the sensitivity, reaching values of 0.01 fg/μL. A set of well-defined frozen
stored human urine samples collected from Sub-Saharan immigrant patients was selected
from a biobank to evaluate the diagnostic validity of SmMIT-LAMP. The set included urine
samples from patients with microscopy-confirmed infections with S. mansoni, S. haemato-
bium and other nonschistosome parasites, as well as urine samples from patients with
microscopy-negative eosinophilia without a confirmed diagnosis. The SmMIT-LAMP was
incubated for 60 and 120 min. A longer incubation time was shown to increase the LAMP-
positive results in patient urine samples. We also tested urine samples from mice experi-
mentally infected with S. mansoni, and LAMP-positive results were obtained from the third
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week after infection. A real-time LAMP assay was also performed with three individual urine
samples.
Conclusions/Significance
The SmMIT-LAMP could effectively detect S. mansoni DNA in mouse urine samples and
produced promising results for human clinical samples. The detection of S. mansoni DNA in
mouse urine samples from the third week after infection indicates that early diagnosis of
active S. mansoni infection is possible using urine as a source of DNA. Further studies are
still needed, but our method could be used as a promising molecular tool applicable to urine
samples to diagnose human intestinal schistosomiasis caused by S. mansoni.
Introduction
Human schistosomiasis, a parasitic disease caused by several species of trematode flatworms of
the genus Schistosoma, is an endemic disease in 74 countries, infecting more than 200 million
people worldwide [1]. Schistosoma mansoni is the main species causing hepatic and intestinal
schistosomiasis in Sub-Saharan Africa, and it is the only species in South America [1–4]. The
prevalence of imported schistosomiasis is growing in nonendemic areas due to the increase in
international travelers to endemic areas, as well as expatriates and immigrants from endemic
countries [5–7].
Different diagnostic techniques are used in diagnosing schistosomiasis. The traditional
Kato-Katz (KK) fecal microscopic examination for counting schistosome eggs and immunol-
ogy-based analyses detecting schistosome-derived circulating anodic (CAA) and cathodic
(CCA) antigens mainly lack sensitivity in low-intensity infections and posttreatment condi-
tions [8, 9]. Antibody detection also lacks specificity, causing a high level of cross-reactivity
[9]. Nonetheless, the detection of CAA and CCA has a number of potential advantages over
specific antibody detection because both can be detected in urine [9, 10]. Today, new technolo-
gies and better diagnostic tests for schistosomiasis in field conditions in endemic areas, as well
as for routine diagnosis in developed countries, are still needed.
Collection of samples for diagnostic purposes, such as stools, blood or tissue biopsies, can
be quite difficult in some population groups. Urine is a biological sample that would have
potential advantages in the detection of S. mansoni over other samples, as it can be collected
noninvasively (versus blood and biopsies), and large quantities of it can easily be obtained. In
addition, it is more convenient to collect from patients of all ages, and it is associated with
greater ease in terms of handling, management and storage than blood and stool samples.
Small amounts of cell-free DNA (cfDNA) in excreted urine can be detected, representing a
potentially useful source of genetic material for diagnostic applications [11–13]. Additionally,
the utility of detecting parasite-specific DNA in human urine samples has already been dem-
onstrated for schistosomes by a number of conventional and real-time PCR (qPCR)-based
methods [14–20, 21] and loop-mediated isothermal amplification (LAMP) assays [22, 23].
The LAMP assay was described by Notomi et al. [24] as a rapid, sensitive, specific and time-
efficient gene amplification technique that amplifies nucleic acids under isothermal condi-
tions, typically using four different primers designed to recognize six distinct regions on the
target sequence. Many salient advantages of LAMP over most PCR-based technologies have
been reported [25]. LAMP technology shows all of the characteristics required for potential
use in clinical diagnosis and surveillance of infectious diseases, particularly under field
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conditions in developing countries for most Neglected Tropical Diseases (NTDs), including
schistosomiasis [26, 27].
In a previous work, we developed a sensitive and specific LAMP assay (named SmMI-
T-LAMP) for the successful early detection of S. mansoni DNA in stool samples from a mouse
model of schistosomiasis [28]. In this study, we examine the application of SmMIT-LAMP for




The study protocol was approved by the institutional research commission of the University of
Salamanca. Ethical approval was obtained from the Ethics Committee of the University of Sal-
amanca (protocol approval number 48531). Animal procedures in this study complied with
the Spanish (Real Decreto RD53/2013) and the European Union (European Directive 2010/
63/EU) guidelines on animal experimentation for the protection and humane use of laboratory
animals and were conducted at the accredited Animal Experimentation Facility (Servicio de
Experimentación Animal) of the University of Salamanca (Register number: PAE/SA/001).
Human urine samples used in this study were obtained as part of public health diagnostic
activities at Hospital Universitario Insular, Las Palmas de Gran Canaria, Gran Canaria, Spain,
and all were obtained under written informed consent and were coded and tested as anony-
mous samples. Participants were given detailed explanations about the aims, procedures and
possible benefit of the study. A standardized epidemiological questionnaire and clinical infor-
mation were obtained from each participant included in the study. Later, samples were sent
and stored at CIETUS, University of Salamanca, Spain, for further molecular analysis. The par-
ticipation of healthy urine donors (lab staff) for obtaining simulated artificial urine samples
and negative urine samples was voluntary. Participants received written and verbal descrip-
tions of the experiment and provided written informed consent prior to testing.
Urine sample collection
Patient urine samples. A total of 28 human urine samples were selected from a set of fro-
zen samples stored at the CIETUS-urine biobank. These urine samples were collected from
Sub-Saharan immigrant patients attending during May 2002 to April 2009 at Hospital Univer-
sitario Insular, Las Palmas de Gran Canaria, Spain, as part of public health diagnostic activities.
While attending, several parasitological diagnostic tests for suspected infectious diseases, such
as for schistosomiasis, were performed according to standard routine laboratory procedures.
Urine was collected and frozen prior to receiving treatment. The selected set of 28 frozen urine
samples was divided into 4 groups as follows: group 1 (n = 7), urine samples from patients
with confirmed schistosomiasis caused by S. mansoni through the detection of parasite eggs in
stools by the KK technique; group 2 (n = 7), urine samples from patients with confirmed schis-
tosomiasis caused by S. haematobium through the detection of parasite eggs in urine by sedi-
mentation or filtration methods; group 3 (n = 7), urine samples from patients with a
microscopy-confirmed infection with other nonschistosome parasites; group 4 (n = 7), urine
samples from patients with eosinophilia without a confirmed diagnosis and negative on all
parasitological tests. Table 1 shows the selected groups of urine samples included in this study.
Additionally, fresh urine from a healthy volunteer staff donor with no history of travel to
endemic areas of schistosomiasis was collected to use as a negative control.
Detection of Schistosoma mansoni-derived DNA in human urine samples by LAMP
PLOS ONE | https://doi.org/10.1371/journal.pone.0214125 March 26, 2019 3 / 16
Simulated urine samples
Fresh urine was collected from a healthy staff donor with no history of travel to endemic areas
of schistosomiasis to assess both the sensitivity and specificity of the LAMP assay. To test the
sensitivity, collected urine was divided into aliquots of 100 μL each and was then spiked with
2 μL of 10-fold serially diluted S. mansoni DNA ranging from 50 ng/μL to 0.5 ag/μL (see
below), thus resulting in a set of simulated urine samples with a final parasite DNA concentra-
tion ranging from 1 ng/μL to 0.01 ag/μL. To test the specificity, a set of tubes was prepared,
each containing 100 μL of urine and spiked with 0.5 ng of DNA from several available hel-
minths, alone and in combination with S. mansoni, including S. haematobium, S. intercalatum,
S. bovis, S. japonicum, Fasciola hepatica, Amphimerus sp. and Strongyloides venezuelensis. All
simulated urine samples were prepared when required and directly processed for DNA extrac-
tion without previous storage.
Table 1. Patient urine samples included in the study. Sample groups, sample numbers, origin of the patients, presence/absence of eosinophilia, parasitological finding
based on microscopy test and LAMP results for Schistosoma mansoni detection are indicated.
Groups Parasitological finding No. Origin Eosinophilia LAMP
G1 (n = 7) Schistosoma mansoni 204 Mali yes Positive
205 Mali yes Negative
207 Cameroon yes Positive
249 Mali no Positive
259 Unknown no Negative
339 Liberia yes Positive
54 Mauritania no Positive
G2 (n = 7) Schistosoma haematobium 01 Mali no Negative
04 Mali no Negative
06 Mali yes Negative
09 Mali no Negative
17 Mali no Negative
90 Mali no Negative
92 Mali yes Negative
G3 (n = 7) Hookworms,
Giardia intestinalis
214 Cameroon no Negative
Strongyloides stercoralis 218 Ghana no Negative
Plasmodium falciparum 236 Cameroon no Negative
Trichomonas vaginalis 237 Nigeria no Positive
Enterobius vermicularis 354 Morocco yes Negative
Loa loa, Mansonella spp., Trichuris trichiura, hookworms 416 Equatorial Guinea yes Negative
Trichuris trichiura 427 Ivory Coast no Positive
G4 (n = 7) Negative 250 Cape Verde yes Positive
256 Nigeria yes Negative
260 Ghana yes Negative
365 Unknown yes Positive
422 Mali yes Positive
444 Ghana yes Positive
488 Ghana yes Negative
G1, G2, G3, G4; groups of urine samples from patients with confirmed infection by Schistosoma mansoni (G1), by S. haematobium (G2), by other nonschistosome
parasites (G3) and with microscopy-negative eosinophilia without confirmed diagnosis (G4).
https://doi.org/10.1371/journal.pone.0214125.t001
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Mouse urine samples. Five-week-old female CD1 mice experimentally infected with S.
mansoni were selected among those routinely maintaining the experimental cycle of the para-
site in our laboratory to be used as sources for urine samples. CD1 mice were infected with 150
S. mansoni cercariae following the methodology previously described by Smithers et al. [29].
Uninfected mice were used as sources for urine samples for negative controls.
Animals were housed at the accredited Animal Experimentation Facility of the University
of Salamanca in individual metabolic polycarbonate cages and placed in a humidity- and tem-
perature-controlled environment with a 12-h photoperiod and received sterilized food and
water ad libitum. To collect urine samples, each mouse was removed from the cage and housed
individually in a plastic beaker cleaned with 70% v/v ethanol. Then, individual urine samples
(approximately 40–100 μL per infected mouse), either found in the plastic beaker or by gently
stroking the lower side of the abdomen, were collected by using a pipette and transferred to a
1.5 mL tube. Individual samples were taken from week 0 to week 8 postinfection (p.i.) and
were then pooled from each time point in a mix to minimize the number of subsequent reac-
tions. The weekly pooled samples (approximately 0.5–1 mL) were stored at -20˚C for further
DNA extraction for molecular analyses.
Following the same procedure, individual urine samples from three additional S. mansoni-
infected mice were collected at week 5 p.i. to extract DNA to test SmMIT-LAMP in a real-time
assay.
DNA extraction
Parasite DNA samples. S. mansoni DNA (Brazilian strain) was extracted from frozen
adult male and female worms available in our laboratory using a DNeasy Blood & Tissue Kit
(QIAGEN, Hilden, Germany) according to the manufacturer’s instructions. The concentra-
tion of S. mansoni DNA was measured using a Nanodrop ND-1000 spectrophotometer
(Nanodrop Technologies) and was then diluted with ultrapure water to a final concentra-
tion of 50 ng/μL. Serial 10-fold dilutions were prepared with ultrapure water ranging from
50 ng/μL to 0.5 ag/μL to prepare the simulated urine samples as mentioned above. S. man-
soni genomic DNA (2 μL; 0.5 ng/μL) was used as a positive control in all LAMP trials. Nega-
tive controls were also utilized in the different trials. Other parasite DNA, including
Schistosoma haematobium, S. intercalatum, S. bovis, S. japonicum, Fasciola hepatica, Amphi-
merus sp. (kindly provided by several colleagues) and Strongyloides venezuelensis (extracted
from infective third-stage larvae from the feces from rats routinely infected with the parasite
in our laboratory), were available in our laboratory and were used for specificity trials (2 μL;
0.5 ng/μL).
DNA from patient urine samples. After thawing, urine aliquots (1 mL) were taken and
then centrifuged at 5,000 rpm for 5 min at RT to pellet the urinary sediment. Excess superna-
tant was discarded, but a minimal volume of approximately 100 μL was maintained to resus-
pend the pellet at the bottom of the tube. DNA was extracted from the 100 μL aliquots using
the i-genomic Urine DNA Extraction Mini Kit (Intron Biotechnology) following the manufac-
turer’s instructions and was then stored at -20˚C until use in LAMP reactions.
DNA from simulated urine samples. DNA was extracted from all fresh simulated urine
samples using the i-genomic Urine DNA Extraction Mini Kit (Intron Biotechnology, UK) fol-
lowing the manufacturer’s instructions. Purified DNA samples were stored at -20˚C until use.
DNA from mouse urine samples. Frozen weekly pooled urine samples (approximately
100 μL) collected at weeks 0–8 p.i. and fresh individual urine samples (approximately 60 μL)
collected ad hoc at week 5 p.i. from S. mansoni-infected mice were used for DNA extraction
using the i-genomic Urine DNA Extraction Mini Kit (Intron Biotechnology) following the
Detection of Schistosoma mansoni-derived DNA in human urine samples by LAMP
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manufacturer’s instructions. Once extracted, purified DNA samples were stored at -20˚C until
use in molecular analyses.
LAMP assays
All LAMP reactions were accomplished using the reaction mixture and specific primer set
(named SmMIT-LAMP assay) established by our group and previously described elsewhere
[28]. Briefly, the reaction was carried out in a volume of 25 μL of reaction mixture containing
40 pmol each of FIP and BIP primers, 5 pmol each of F3 and B3 primers, 1.4 mM of each
dNTP, 1x Isothermal Amplification Buffer—20 mM Tris-HCl (pH 8.8), 50 mM KCl, 10 mM
(NH4)2SO4, 2 mM MgSO4, 0.1% Tween20 (New England Biolabs, UK), 1 M betaine (Sigma,
USA), supplementary 6 mM MgSO4 (New England Biolabs, UK) and 8 U of Bst 2.0 WarmStart
DNA polymerase (New England Biolabs, UK) with 2 μL of template DNA. Reaction tubes
were placed in a heating block at 65˚C for 60 min or 120 min and were then heated at 80˚C for
5 min to stop the reaction. The results were assessed by visual detection of fluorescence (green:
positive; orange: negative) after adding 2 μL of 1:10 diluted 10,000X concentration SYBR
Green I (Invitrogen) to the final volume. To avoid potential cross-contamination with ampli-
fied products, the tubes were briefly centrifuged and carefully opened before adding the dye.
The LAMP products (3–5 μL) were also monitored using 1.5% agarose gel electrophoresis and
were documented with a gel documentation system (UVItec, UK).
LAMP mixes (25 μL) for real-time reactions were prepared as those for SmMIT-LAMP but
also including EvaGreen 20X (Biotium) to monitor the amplification. Real-time reactions
were performed in 8-tube Genie Strips using the portable Genie III device (Optigene Ltd.,
Horsham, UK) at 63˚C for 60 min, followed by 10 min at 80˚C. The results were also con-
firmed on 1.5% agarose gels.
Results
Application of SmMIT-LAMP on spiked human urine samples
The sensitivity of the LAMP assay in simulated fresh human urine samples artificially spiked
with DNA from S. mansoni is shown in Fig 1. The detection limit of LAMP was 100 fg/μL
when incubating the tubes for 60 min (Fig 1A), whereas the detection limit was established at
0.01 fg/μL when incubating for 120 min (Fig 1B).
Fig 2 shows the specificity of the SmMIT-LAMP when incubating for 60 min, which exclu-
sively amplifies DNA from S. mansoni in simulated situations using urine samples spiked addi-
tionally with DNA from several other helminths. Only positive results in urine samples
containing DNA from S. mansoni were obtained. The same results were obtained when incu-
bating for 120 min.
Application of SmMIT-LAMP in patient urine samples. The results of patient urine
samples evaluated for S. mansoni DNA detection using the SmMIT-LAMP assay are shown in
Fig 3. When the amplification assays were performed using the standard reaction time of 60
min for SmMIT-LAMP, no positive results were obtained in any group of urine samples (Fig
3A). However, we obtained positive results when using S. mansoni DNA as a positive control,
thus indicating the proper operation of the LAMP assay. As we did not achieve amplification
results in clinical samples, we increased the reaction time to 120 min to improve DNA
amplification.
In subsequent tests performed for 120 min (Fig 3B), we obtained LAMP-positive results in
5/7 confirmed S. mansoni-infected urine samples, in 3/7 urine samples with other nonschisto-
some parasites confirmed parasitologically by microscopy—specifically, three patients infected
with Trichomonas vaginalis (no. 237), Enterobius vermicularis (no. 354) and Trichuris trichiura
Detection of Schistosoma mansoni-derived DNA in human urine samples by LAMP
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(no. 427)—and in 4/7 urine samples from patients with eosinophilia without a confirmed diag-
nosis and who were negative for different parasitological tests. No LAMP-positive results in
confirmed S. haematobium-infected urine samples were obtained, thus signifying the specific-
ity of the SmMIT-LAMP. In all assays, the positive S. mansoni DNA control always amplified,
while the negative control (urine sample from a healthy donor) never amplified.
Application of SmMIT-LAMP on mouse urine samples. We tested each weekly pool of
urine samples obtained from mice infected with S. mansoni by SmMIT-LAMP (60 min), and
positive results were obtained from week 3 p.i. to week 8 p.i. (Fig 4). The positive control was
correctly amplified. The pool of urine samples from uninfected mice resulted in a negative
LAMP amplification. Identical results were obtained with a reaction time of 120 min.
When the LAMP assay was run in real-time for 60 min at 65˚C, DNA extracted from urine
collected from three S. mansoni-infected mice at week 5 p.i. resulted in amplification times of
35:44, 35:29 and 41:14 min, respectively, with melt temperatures ranging between 82.40˚C and
82.70˚C (Fig 5). Negative controls showed no amplification. Analysis by 1.5% agarose gel elec-
trophoresis confirmed these results.
Discussion
PCR-based tests in stool specimens have proven more sensitive than microscopy on KK
smears for S. mansoni detection, especially for low worm burdens, such as chronic infection
cases [30] and in low transmission areas [31]. Regardless of the test used, the collection of stool
samples for diagnostic purposes is usually difficult, and patients perceive that handling stools
is dirty and embarrassing [32]. Additionally, the handling, management and storage of large
numbers of patient stool samples for diagnosing schistosomiasis can be very laborious in
large-scale field trials. In addition, PCR inhibitors are frequently present in stool samples and
can lead to false-negative PCR results [33]. Considering the advantages over the stool samples
and the proven effectiveness of the PCR-based detection of schistosome-derived DNA in
Fig 1. Sensitivity of the SmMIT-LAMP assay in simulated human urine samples. (A) Sensitivity assessment of LAMP when incubating for 60 min. (B)
Sensitivity assessment of LAMP when incubating for 120 min. Lanes M: DNA ladder; lanes Sm: genomic DNA from S. mansoni (1 ng); lanes 1–10−9: 10-fold
serial dilutions (1 ng/μL to 0.01 ag/μL); lanes N1 and N2: negative controls (no DNA, water as template).
https://doi.org/10.1371/journal.pone.0214125.g001
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urine, the use of patient urine samples would be an alternative approach for S. mansoni molec-
ular detection. However, PCR-based technology is not widely used in resource-limited settings
because skilled personnel and expensive cyclers are still needed. The inexpensiveness and
Fig 2. Specificity of the SmMIT-LAMP assay in simulated human urine samples spiked with DNA from several helminths.
Figure shows the LAMP results when incubating for 60 min (top, by color change; bottom, by agarose electrophoresis) in urine
samples spiked with S. mansoni DNA alone and in combination with DNA from other helminths. Samples were prepared, each
containing 100 μL of urine spiked with 0.5 ng of DNA from each parasite. Sm, S. mansoni; Sh, S. haematobium; Si, S. intercalatum; Sb,
S. bovis; Sj, S. japonicum; Fh, Fasciola hepatica; Amp, Amphimerus sp.; Sv, Strongyloides venezuelensis.
https://doi.org/10.1371/journal.pone.0214125.g002
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user-friendliness of the LAMP technique, together with the increasing miniaturization of the
isothermal technology as a lab-on-chip, makes it a cost-effective and simple tool that provides
an alternative to PCR assays for chip-based point of care (POC) diagnostic applications [34–
37]. Even so, at present, the microLAMP systems for POC diagnostics still have limitations
Fig 3. Examination of patient urine samples by SmMIT-LAMP. This figure shows the LAMP results (top, by color
change; bottom, by agarose electrophoresis) when analyzing the clinical urine samples by performing the LAMP
reaction at 63˚C for (A) 60 min or (B) 120 min. G1, G2, G3, G4; groups of urine samples from patients with confirmed
infection by Schistosoma mansoni (G1), by S. haematobium (G2), by other nonschistosome parasites (G3) and with
eosinophilia, without confirmed diagnosis as well as parasitologically negative (G4). Lanes M, DNA ladder; lanes Sm,
positive control (genomic DNA from S. mansoni; 1 ng); lanes N, negative controls (urine sample from a healthy
donor); lanes with numbers, patient urine samples used.
https://doi.org/10.1371/journal.pone.0214125.g003
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and do not completely satisfy World Health Organization (WHO) criteria for equipment- and
electricity-free operation [36].
The objective of this work is to determine the feasibility of using urine as a source of DNA
in combination with the effectiveness of our LAMP assay for successful S. mansoni detection
in clinical urine samples. First, the sensitivity of the SmMIT-LAMP assay in simulated fresh
human urine samples spiked with DNA from S. mansoni was examined. The detection limits
of our LAMP assay were 100 fg/μL when incubating for 60 min and 0.01 fg/μL for 120 min. It
has been suggested that a longer incubation time for the LAMP reaction improves the sensitiv-
ity, thus avoiding the possibility of obtaining false negatives [38, 39]. Moreover, a reaction
time of 120 min has already been successfully used with LAMP for the integrated diagnosis of
single or mixed schistosome infection by amplifying S. mansoni and S. haematobium DNA
from human urine samples [21]. Considering the above, since we first tested the patient urine
samples using SmMIT-LAMP for 60 min, and no positive results were obtained, we then
increased the incubation time to 120 min and obtained amplification in several urine samples.
The DNA of S. mansoni used as a positive control was always amplified (incubating 60 or 120
min), thus indicating the correct operation of the LAMP assay. Negative controls never ampli-
fied, indicating that nonspecific binding due to annealing of primers did not occur. Moreover,
we always obtained SmMIT-LAMP-negative results when using incubation times of 60 and
120 min in all parasitologically confirmed S. haematobium-positive urine samples tested, thus
corroborating again that no cross-reaction with that schistosome species occurred [28] and
also avoiding potential false-negative results. The possibility of a cross-reaction was completely
discarded, as the analysis of urine samples spiked with DNA from other parasites, including
several Schistosoma species different from S. mansoni, was negative. Hence, all subsequent
SmMIT-LAMP assays to test human clinical samples were performed for 120 min.
The use of frozen storage urine samples collected in a biobank allowed us to select a set of
well-defined human samples for the study. We obtained 5/7 (71.4%) SmMIT-LAMP-positive
Fig 4. Examination of mouse urine samples by SmMIT-LAMP. Figure shows the 60-min LAMP results (top, by
color change; bottom, by agarose electrophoresis) of the analysis of each weekly pool of urine samples obtained from
mice infected with 150 cercariae each over a period of 8 weeks. Identical results were obtained for the 120-min LAMP
assay. Lane M, DNA ladder; lane N, negative control (urine sample from a noninfected mouse); lane Sm, genomic
DNA from S. mansoni (1 ng); lanes S1-S8, pooled urine samples from individual mice obtained at weeks 1–8
postinfection.
https://doi.org/10.1371/journal.pone.0214125.g004
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results in those patient urine samples with microscopy-confirmed S. mansoni infection. How-
ever, authentic S. mansoni-infected samples (nos. 205 and 259) were not amplified. We think
that the lack of positive results in these samples cannot be due to the lack of a proper operation
of the SmMIT-LAMP, given the high sensitivity shown by the method, which worked properly
with the other five microscopy-confirmed S. mansoni samples. It is possible that several other
factors, such as bacterial and/or fungal contamination during the storage of urine samples,
long-term frozen storage conditions without a preserving solution or repetitive freeze-thaw
cycles for different trials, could be the reason for the lack of S. mansoni DNA detection. In a
previous work, we described similar complications in obtaining positive results in S. mansoni
DNA detection when 18 patient urine samples infected with the parasite were tested by PCR
[40]. However, it must be considered that we have now achieved a greater number of positive
results by SmMIT-LAMP than using PCR for S. mansoni DNA detection in urine samples.
This could be due to the increased sensitivity and the greater robustness of LAMP over PCR-
based methods for diagnostic applications [41, 42]. Nevertheless, because the patients them-
selves often collect their urine samples outside of a medical setting, molecular analysis can be
very susceptible to preanalytical contamination issues. In this sense, it would be interesting to
identify reagents that stabilize cell-free DNA in urine specimens, allowing convenient sample
collection, transport and storage for further molecular analysis.
Regarding the SmMIT-LAMP-positive results obtained from patient urine samples with
parasitologically confirmed infection with nonschistosome parasites, i.e., Trichomonas vagina-
lis (no. 237), Enterobius vermicularis (no. 354) and Trichuris trichiura (no. 427), it is not
uncommon in endemic areas to find patients coinfected with schistosomes and other organ-
isms, such as bacteria, protozoa and helminths [43]. We think that these results could be
authentic microscopically undetected S. mansoni infections and not likely due to cross-reac-
tions, as we obtained a SmMIT-LAMP-negative result in another sample (no. 416) with a
microscopy-confirmed infection with T. trichiura, among other parasites.
We also obtained SmMIT-LAMP-positive results in several patient urine samples with
eosinophilia but without a confirmed diagnosis and who were negative for any parasite in
microbiological tests. Eosinophilia is usually used as a biomarker for helminthic infections,
including schistosomiasis [44], but it is not predictive of Schistosoma species infection and can
lead to inconsistent results [45]. The SmMIT-LAMP-positive results obtained could be authen-
tic S. mansoni infections that were microscopically undetected because of the classically low
sensitivity of the parasitological diagnosis (especially in low-intensity infections) or affected by
day-to-day variability in egg excretion [46]. Another explanation could be a detection of a pre-
patent schistosome infection.
The viability of the SmMIT-LAMP assay for detection of S. mansoni-derived DNA in urine
samples was also tested in a mouse model of schistosomiasis. We obtained positive results in
pooled samples collected from week 3 to week 8 p.i., suggesting that an early diagnosis of active
S. mansoni infection is feasible using urine samples and a LAMP assay, as previously reported
using mouse feces [28]. Since the mouse urine studies were on pooled samples, there was no
way to determine a potential false-negative rate for these samples. Consequently, we tested
fresh urine samples collected ad hoc at week 5 p.i. from three experimentally S. mansoni-
Fig 5. Amplification curves, melt outputs and agarose gel electrophoresis for S. mansoni in urine samples from
experimentally infected mice collected at week 5 p.i. Outputs from the LAMP experimental run showing A)
amplification and B) melt outputs using positive and negative samples. C) Agarose gel electrophoresis. Lanes 1 and 2,
negative controls (water as template); lanes 3 and 4, negative controls (DNA from uninfected mouse urine as
template); lane 5, positive control (S. mansoni DNA; 1 ng); lanes 6–8, three mouse urine samples. Lane M, DNA
ladder.
https://doi.org/10.1371/journal.pone.0214125.g005
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infected mice by a real-time SmMIT-LAMP, and we individually verified that amplifications
began after 35 min of incubation at 65˚C. These positive results in fresh mouse urine samples
could explain the failure in amplification in stored frozen microscopy-confirmed S. mansoni
clinical urine samples, possibly due to contamination prior to storage or DNA damage hinder-
ing proper amplification, as previously suggested. Therefore, a longer incubation time for a
conventional SmMIT-LAMP reaction allowed us to improve the efficiency of the amplifica-
tion, thus avoiding false negatives in parasitological S. mansoni-confirmed infections and in
other clinical urine samples analyzed. Thus, the successful detection of S. mansoni DNA in
long-term frozen stored and likely partially degraded urine samples analyzed makes our
SmMIT-LAMP assay a potentially robust tool for molecular diagnosis in low-complexity labo-
ratories, mainly in endemic areas of schistosomiasis. However, further studies are needed
using inexpensive, easy and good-quality DNA from urine samples to reduce the costs of the
analysis and to reduce the amplification time required, especially if unpreserved urine samples
are used. Additionally, it would be ideal to increase the number of urine samples to examine
how reproducible the technique is when testing in field settings.
The preliminary results presented here suggest that our SmMIT-LAMP assay could be a
promising molecular tool applicable to patient urine samples to diagnose intestinal schistoso-
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